• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

嵌合抗原受体（CAR）T 细胞治疗后复发/难治性非霍奇金淋巴瘤采用挽救性放疗的早期经验。

Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.

机构信息

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Br J Haematol. 2020 Jul;190(1):45-51. doi: 10.1111/bjh.16541. Epub 2020 Mar 5.

DOI:10.1111/bjh.16541
PMID:32135029
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7329607/
Abstract

Radiotherapy is potentially an important salvage strategy post-chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post-CART progression (SRT). Most received SRT for first post-CART relapse (71%) to sites previously PET-avid pre-CART (79%). Median overall survival (OS) post-SRT was 10 months. Post-SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P = 0·001) and OS (P = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.

摘要

放疗是嵌合抗原受体 T 细胞疗法（CART）后一种有潜力的重要挽救策略，但相关数据有限。我们回顾了 14 例接受 CART 进展后挽救性放疗（SRT）治疗的患者。大多数患者因首次 CART 复发（71%）至先前 CART 前 PET 阳性部位而接受 SRT（79%）。SRT 后中位总生存期（OS）为 10 个月。SRT 后，6 例局限性复发达到 100%缓解（3 例完全缓解，3 例部分缓解），与晚期复发相比，无后续复发（P=0·001）和 OS（P=0·004）均得到改善。3 例患者接受异基因移植桥接治疗；在分析时，所有患者均存活/无疾病。SRT 具有多种用途，可与新的药物或移植相结合，以尝试持久缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27cc/7329607/070186a21676/nihms-1552842-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27cc/7329607/070186a21676/nihms-1552842-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27cc/7329607/070186a21676/nihms-1552842-f0001.jpg

相似文献

1
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.嵌合抗原受体（CAR）T 细胞治疗后复发/难治性非霍奇金淋巴瘤采用挽救性放疗的早期经验。
Br J Haematol. 2020 Jul;190(1):45-51. doi: 10.1111/bjh.16541. Epub 2020 Mar 5.
2
Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach.将放射性物质与抗 CD19 嵌合抗原受体 T 细胞疗法联合用于复发/难治性非霍奇金淋巴瘤：多中心共识方法。
Am J Hematol. 2024 Jan;99(1):124-134. doi: 10.1002/ajh.27155. Epub 2023 Nov 11.
3
Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.嵌合抗原受体 T 细胞治疗后挽救方案评估弥漫性大 B 细胞淋巴瘤患者。
Transplant Cell Ther. 2022 Jun;28(6):342.e1-342.e5. doi: 10.1016/j.jtct.2022.02.021. Epub 2022 Mar 4.
4
Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.CD19嵌合抗原受体T细胞（CART）治疗后复发/难治性非霍奇金淋巴瘤的挽救性放疗
Clin Transl Radiat Oncol. 2023 Jan 20;39:100587. doi: 10.1016/j.ctro.2023.100587. eCollection 2023 Mar.
5
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.嵌合抗原受体 T 细胞作为嵌合抗原受体 T 细胞治疗失败后的挽救疗法。
Transplant Cell Ther. 2023 Sep;29(9):574.e1-574.e10. doi: 10.1016/j.jtct.2023.06.019. Epub 2023 Jun 30.
6
Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma.不要本末倒置：放疗在 CAR-T 细胞治疗侵袭性 B 细胞非霍奇金淋巴瘤中的作用。
Int J Radiat Oncol Biol Phys. 2023 Aug 1;116(5):999-1007. doi: 10.1016/j.ijrobp.2022.12.017. Epub 2022 Dec 21.
7
ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy.ASTCT 委员会关于嵌合抗原受体 T 细胞（CAR-T）治疗后弥漫性大 B 细胞淋巴瘤评估与管理的实践指南调查。
Transplant Cell Ther. 2022 Sep;28(9):523-529. doi: 10.1016/j.jtct.2022.05.043. Epub 2022 Jun 6.
8
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.异基因移植后复发的 B 细胞急性淋巴细胞白血病的 CD19 和 CD22 CAR-T 细胞治疗的联合应用。
Am J Hematol. 2021 Jun 1;96(6):671-679. doi: 10.1002/ajh.26160. Epub 2021 Mar 29.
9
[Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].CD19嵌合抗原受体T细胞治疗22例B细胞淋巴瘤的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2019 Apr 14;40(4):276-280. doi: 10.3760/cma.j.issn.0253-2727.2019.04.003.
10
The Current and Future Role of Radiation Therapy in the Era of CAR T-cell Salvage.在 CAR T 细胞挽救时代的放射治疗的现在和未来作用。
Br J Radiol. 2021 Nov 1;94(1127):20210098. doi: 10.1259/bjr.20210098. Epub 2021 Aug 10.

引用本文的文献

1
CAR T-Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real-World Experiences From a Single Center on the Use of Radiotherapy.复发难治侵袭性淋巴瘤患者的CAR-T细胞疗法：来自单一中心放疗应用的真实世界经验
Hematol Oncol. 2025 Sep;43(5):e70124. doi: 10.1002/hon.70124.
2
The Role of Radiotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Post-CAR-T Therapy: A Systematic Literature Review.放疗在CAR-T治疗后复发或难治性弥漫性大B细胞淋巴瘤中的作用：一项系统文献综述
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251351065. doi: 10.1177/15330338251351065. Epub 2025 Jun 18.
3

本文引用的文献

1
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.自体移植后 CD19 CAR T 细胞治疗高危复发/难治性 B 细胞非霍奇金淋巴瘤。
Blood. 2019 Aug 15;134(7):626-635. doi: 10.1182/blood.2018883421. Epub 2019 Jul 1.
2
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.弥漫性大 B 细胞淋巴瘤中用 axi-cel 进行嵌合抗原受体 T 细胞治疗的桥接策略中的放射治疗。
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1012-1021. doi: 10.1016/j.ijrobp.2019.05.065. Epub 2019 Jun 5.
3
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.
[Radiotherapy of non-Hodgkin lymphoma-discussion of modern treatment concepts and innovations].
[非霍奇金淋巴瘤的放射治疗——现代治疗理念与创新探讨]
Radiologie (Heidelb). 2025 Jun 11. doi: 10.1007/s00117-025-01477-3.
4
Role of Radiation in Combination With CD30-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma.放疗联合CD30导向的嵌合抗原受体T细胞疗法在复发/难治性霍奇金淋巴瘤中的作用
Adv Radiat Oncol. 2023 Dec 23;9(4):101428. doi: 10.1016/j.adro.2023.101428. eCollection 2024 Apr.
5
Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma.B细胞淋巴瘤中CAR T细胞治疗后复发的治疗策略。
Front Pediatr. 2024 Jan 12;11:1305657. doi: 10.3389/fped.2023.1305657. eCollection 2023.
6
Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era.在利妥昔单抗时代，难治性或复发性侵袭性 B 细胞淋巴瘤的低分割放疗。
BMC Cancer. 2024 Jan 13;24(1):72. doi: 10.1186/s12885-024-11837-2.
7
Management of aggressive lymphoma after CAR T-cell therapy failure.CAR T 细胞治疗失败后侵袭性淋巴瘤的治疗管理。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):364-369. doi: 10.1182/hematology.2023000437.
8
The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors.嵌合抗原受体巨噬细胞（CAR巨噬细胞），一种针对实体瘤的新一代基于嵌合抗原的方法。
Biomark Res. 2023 Nov 28;11(1):103. doi: 10.1186/s40364-023-00537-x.
9
Application of interim PET-CT in first-line treatment decision-making for lymphoma.中期PET-CT在淋巴瘤一线治疗决策中的应用。
J Zhejiang Univ Sci B. 2023 Oct 15;24(10):905-921. doi: 10.1631/jzus.B2200644.
10
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma.复发或难治性弥漫性大B细胞淋巴瘤基于免疫治疗的新策略进展
Exp Hematol Oncol. 2023 Aug 14;12(1):72. doi: 10.1186/s40164-023-00432-z.
BCMA 靶向 CAR T 细胞疗法联合放疗治疗难治性骨髓瘤显示出潜在协同作用。
Cancer Immunol Res. 2019 Jul;7(7):1047-1053. doi: 10.1158/2326-6066.CIR-18-0551. Epub 2019 May 21.
4
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.CD19特异性嵌合抗原受体T细胞疗法治疗后患有大B细胞淋巴瘤及疾病进展患者的结局。
Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21.
5
Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation.放疗、免疫检查点阻断与远隔效应：关于时机、剂量和分割的批判性综述
Front Oncol. 2018 Dec 13;8:612. doi: 10.3389/fonc.2018.00612. eCollection 2018.
6
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
7
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.低剂量辐射预处理使 CAR T 细胞能够减轻抗原逃逸。
Mol Ther. 2018 Nov 7;26(11):2542-2552. doi: 10.1016/j.ymthe.2018.09.008. Epub 2018 Sep 13.
8
The promise of CAR T-cell therapy in aggressive B-cell lymphoma.嵌合抗原受体T细胞疗法在侵袭性B细胞淋巴瘤中的前景。
Best Pract Res Clin Haematol. 2018 Sep;31(3):293-298. doi: 10.1016/j.beha.2018.07.011. Epub 2018 Aug 1.
9
The influence of radiation in the context of developing combination immunotherapies in cancer.辐射在癌症联合免疫疗法研发背景下的影响。
Ther Adv Vaccines Immunother. 2017 Dec;5(6):115-122. doi: 10.1177/2051013617750561. Epub 2018 Jan 24.
10
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.复发/难治性弥漫性大 B 细胞淋巴瘤患者的放射治疗作用：国际淋巴瘤放射肿瘤学组指南。
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):652-669. doi: 10.1016/j.ijrobp.2017.12.005.